Amyloid Beta Protein Precursor with Kunitz-Type Protease Inhibitor Domains (APPI) in Cerebrospinal Fluid and APPI mRNAs in Cultured Skin Fibroblasts of Patients with Alzheimer's Disease

Katsuya Urakami, Akitsugu Okada, Kazuro Takahashi, Kousaku Ohno, Nobuya Kitaguchi, Seigo Tanaka, Shigenobu Nakamura

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Urakami, K., Okada, A., Ohno, K., Kitaguchi, N., Tanaka, S., Nakamura, S. and Takahashi, K. Amyloid Beta Protein Precursor with Kunitz-Type Protease Inhibitor Domains (APPI) in Cerebrospinal Fluid and APPI mRNAs in Cultured Skin Fibroblasts of Patients with Alzheimer's Disease. Tohoku J. Exp. Med., 1994, 174 (3), 199-207 We studied amyloid beta protein precursor with Kunitz-type protease ihibitor domains (APPI) concentration in cerebrospinal fluid (CSF) and APPI mRNA in skin fibroblast in Alzheimer's disease (AD). The subjects consisted of AD, cerebrovascular dementia (VD) and age-matched controls. We measured the APPI concentration in the CSF by the trypsin antibody sandwich ELISA. APPI mRNA was examined by the RT-PCR teqchnique. The CSF APPI concentration in AD was significantly higher than that of VD and controls. The CSF APPI concentration in AD was high in the initial stage of dementia and decreased during the course. The expression of APPI mRNA in skin fibroblasts in AD was also significantly higher than that of VD and controls. These results suggest that measurements of APPI levels in CSF and APPI mRNA in skin fibroblasts may be useful for early diagnosis of AD. amyloid beta protein precursor with Kunitz-type protease inhibitor domains; Alzheimer's disease; cerebrospinal fluid; skin fibroblast; longitudinal study.

Original languageEnglish
Pages (from-to)199-207
Number of pages9
JournalTohoku Journal of Experimental Medicine
Volume174
Issue number3
DOIs
Publication statusPublished - 01-01-1994

Fingerprint

Cerebrospinal fluid
Amyloid beta-Protein Precursor
Fibroblasts
Protease Inhibitors
Cerebrospinal Fluid
Skin
Alzheimer Disease
Messenger RNA
Dementia
Trypsin
Longitudinal Studies
Early Diagnosis
Peptide Hydrolases
Enzyme-Linked Immunosorbent Assay
Polymerase Chain Reaction
Antibodies

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{62e0d15a83d94e61939ee46fe8a29510,
title = "Amyloid Beta Protein Precursor with Kunitz-Type Protease Inhibitor Domains (APPI) in Cerebrospinal Fluid and APPI mRNAs in Cultured Skin Fibroblasts of Patients with Alzheimer's Disease",
abstract = "Urakami, K., Okada, A., Ohno, K., Kitaguchi, N., Tanaka, S., Nakamura, S. and Takahashi, K. Amyloid Beta Protein Precursor with Kunitz-Type Protease Inhibitor Domains (APPI) in Cerebrospinal Fluid and APPI mRNAs in Cultured Skin Fibroblasts of Patients with Alzheimer's Disease. Tohoku J. Exp. Med., 1994, 174 (3), 199-207 We studied amyloid beta protein precursor with Kunitz-type protease ihibitor domains (APPI) concentration in cerebrospinal fluid (CSF) and APPI mRNA in skin fibroblast in Alzheimer's disease (AD). The subjects consisted of AD, cerebrovascular dementia (VD) and age-matched controls. We measured the APPI concentration in the CSF by the trypsin antibody sandwich ELISA. APPI mRNA was examined by the RT-PCR teqchnique. The CSF APPI concentration in AD was significantly higher than that of VD and controls. The CSF APPI concentration in AD was high in the initial stage of dementia and decreased during the course. The expression of APPI mRNA in skin fibroblasts in AD was also significantly higher than that of VD and controls. These results suggest that measurements of APPI levels in CSF and APPI mRNA in skin fibroblasts may be useful for early diagnosis of AD. amyloid beta protein precursor with Kunitz-type protease inhibitor domains; Alzheimer's disease; cerebrospinal fluid; skin fibroblast; longitudinal study.",
author = "Katsuya Urakami and Akitsugu Okada and Kazuro Takahashi and Kousaku Ohno and Nobuya Kitaguchi and Seigo Tanaka and Shigenobu Nakamura",
year = "1994",
month = "1",
day = "1",
doi = "10.1620/tjem.174.199",
language = "English",
volume = "174",
pages = "199--207",
journal = "Tohoku Journal of Experimental Medicine",
issn = "0040-8727",
publisher = "Tohoku University Medical Press",
number = "3",

}

Amyloid Beta Protein Precursor with Kunitz-Type Protease Inhibitor Domains (APPI) in Cerebrospinal Fluid and APPI mRNAs in Cultured Skin Fibroblasts of Patients with Alzheimer's Disease. / Urakami, Katsuya; Okada, Akitsugu; Takahashi, Kazuro; Ohno, Kousaku; Kitaguchi, Nobuya; Tanaka, Seigo; Nakamura, Shigenobu.

In: Tohoku Journal of Experimental Medicine, Vol. 174, No. 3, 01.01.1994, p. 199-207.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Amyloid Beta Protein Precursor with Kunitz-Type Protease Inhibitor Domains (APPI) in Cerebrospinal Fluid and APPI mRNAs in Cultured Skin Fibroblasts of Patients with Alzheimer's Disease

AU - Urakami, Katsuya

AU - Okada, Akitsugu

AU - Takahashi, Kazuro

AU - Ohno, Kousaku

AU - Kitaguchi, Nobuya

AU - Tanaka, Seigo

AU - Nakamura, Shigenobu

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Urakami, K., Okada, A., Ohno, K., Kitaguchi, N., Tanaka, S., Nakamura, S. and Takahashi, K. Amyloid Beta Protein Precursor with Kunitz-Type Protease Inhibitor Domains (APPI) in Cerebrospinal Fluid and APPI mRNAs in Cultured Skin Fibroblasts of Patients with Alzheimer's Disease. Tohoku J. Exp. Med., 1994, 174 (3), 199-207 We studied amyloid beta protein precursor with Kunitz-type protease ihibitor domains (APPI) concentration in cerebrospinal fluid (CSF) and APPI mRNA in skin fibroblast in Alzheimer's disease (AD). The subjects consisted of AD, cerebrovascular dementia (VD) and age-matched controls. We measured the APPI concentration in the CSF by the trypsin antibody sandwich ELISA. APPI mRNA was examined by the RT-PCR teqchnique. The CSF APPI concentration in AD was significantly higher than that of VD and controls. The CSF APPI concentration in AD was high in the initial stage of dementia and decreased during the course. The expression of APPI mRNA in skin fibroblasts in AD was also significantly higher than that of VD and controls. These results suggest that measurements of APPI levels in CSF and APPI mRNA in skin fibroblasts may be useful for early diagnosis of AD. amyloid beta protein precursor with Kunitz-type protease inhibitor domains; Alzheimer's disease; cerebrospinal fluid; skin fibroblast; longitudinal study.

AB - Urakami, K., Okada, A., Ohno, K., Kitaguchi, N., Tanaka, S., Nakamura, S. and Takahashi, K. Amyloid Beta Protein Precursor with Kunitz-Type Protease Inhibitor Domains (APPI) in Cerebrospinal Fluid and APPI mRNAs in Cultured Skin Fibroblasts of Patients with Alzheimer's Disease. Tohoku J. Exp. Med., 1994, 174 (3), 199-207 We studied amyloid beta protein precursor with Kunitz-type protease ihibitor domains (APPI) concentration in cerebrospinal fluid (CSF) and APPI mRNA in skin fibroblast in Alzheimer's disease (AD). The subjects consisted of AD, cerebrovascular dementia (VD) and age-matched controls. We measured the APPI concentration in the CSF by the trypsin antibody sandwich ELISA. APPI mRNA was examined by the RT-PCR teqchnique. The CSF APPI concentration in AD was significantly higher than that of VD and controls. The CSF APPI concentration in AD was high in the initial stage of dementia and decreased during the course. The expression of APPI mRNA in skin fibroblasts in AD was also significantly higher than that of VD and controls. These results suggest that measurements of APPI levels in CSF and APPI mRNA in skin fibroblasts may be useful for early diagnosis of AD. amyloid beta protein precursor with Kunitz-type protease inhibitor domains; Alzheimer's disease; cerebrospinal fluid; skin fibroblast; longitudinal study.

UR - http://www.scopus.com/inward/record.url?scp=0028541020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028541020&partnerID=8YFLogxK

U2 - 10.1620/tjem.174.199

DO - 10.1620/tjem.174.199

M3 - Article

C2 - 7761985

AN - SCOPUS:0028541020

VL - 174

SP - 199

EP - 207

JO - Tohoku Journal of Experimental Medicine

JF - Tohoku Journal of Experimental Medicine

SN - 0040-8727

IS - 3

ER -